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SIGNIFICANT improvements in the results of renal transplantation in the 1980s were largely due to the 
development of cyclosporine (CyA) and the use of antilym-
phocyte agents for induction protocols and/or treatment of 
rejection. However, rejection refractory to treatment with 
corticosteroids and/or antilymphocyte agents has remained 
a major obstacle to long-term success and account for a 
significant proportion of short- and long-term graft loss-
es.1•2 Tacrolimus is a new immunosuppressant that has 
undergone extensive clinical testing for efficacy in renal 
transplantation. In both U.S. and European multicenter 
trials,3.4 tacrolimus has been found to be associated with a 
significant reduction in acute rejection episodes. 
An additional proven advantage of tacrolimus includes 
steroid tapering and monotherapy in up to 60% of recipi-
ents.s Perhaps even more striking is the utility of this drug 
as a salvage agent for refractory renal allograft rejection.6 - 9 
We reported that of 77 patients with refractory acute 
rejection on baseline cyclosporine (CyA) therapy, graft 
salvage with tacrolimus conversion could be achieved in 
74%.8 An additional 92 patients were subsequently con-
verted to tacrolimus to attempt graft salvage, bringing the 
total to 169 patients.9 
We report here the results of this expanded experience 
with tacrolimus conversion for recalcitrant renal allograft 
rejection. Other reports from both single-center and mul-
ticenter studies have confirmed that tacrolimus provides an 
excellent alternative to corticosteroids and antilymphocyte 
preparations for the treatment of refractory renal allograft 
rejection and they form the basis of this discussion. 
MATERIALS AND METHODS 
A total of 169 patients (98 male. 71 female) with a mean age of 
36.2 :!: 13.1 years (range 2 to 75 years) with ongoing allograft 
rejection under baseline CyA immunosuppression were converted 
to tacrolimus immunosuppression between July 14. 1989. and May 
24.1994. One hundred and thirty-two patients (78%) were recipi-
ents of cadaver (CAD) grafts and 37 (22%) were from living donors 
(LD). There were 138 (82%) primary transplant recipients and 31 
(18%) had been retransplanted (21 second. 7 third. 2 fourth. and 1 
fifth transplants). Nineteen patients received combined kidney-
pancreas allografts. All patients had uncontrolled rejection on 
primary immunosuppressive therapy, which had consisted of CyA 
and prednisone either with (n = 117. 69%) or without (n = 52. 
31%) azathioprine (AZA). Two patients had previously been given 
mycophenolate mofetil (MMF) in unsuccessful attempts to reverse 
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rejection. The majoriry of the patients in this series (156 of 169. 
92%) were referred to our institution from 32 other U.S. centers 
where they were deemed to be losing their grafts owing to the 
severity of their rejection. All patients had been maintained on 
maximized but safe and tolerable CyA dosing. Previous antirejec-
tion therapy had been administered to all 169 patients in the form 
of bolus high-dose corticosteroids with additional monoclonal 
(OKT3) and/or polyclonal (ATG or ATGAM) antilymphocyte 
preparations in 144 (85%) of the 169 patients. 
Prior to conversion to tacrolimus. allograft dysfunction second-
ary to technical causes was ruled out by Doppler ultrasound and 
radionuclide flow study of the allograft. Biopsy material was 
reviewed from the referring center. and core biopsies of the 
allograft were repeated at our own institution in all patients to 
verify the continuing presence of ongoing rejection prior to con-
version to tacrolimus. Acute cellular rejections (ACR) was present 
on biopsy of all 169 patients prior to conversion. including 62 
patients (37%) whose biopsies also revealed a vascular component 
of rejection (lymphocytic infiltration in arterial walls. intraglomeru-
lar hemorrhage and/or infarction) and 16 patients (9.5%) who were 
dialysis-dependent from the time of transplantation (primary non-
function with ongoing ACR). 
As previously described," all patients underwent a simple switch 
("clean conversion") from CyA to tacrolimus. Tacrolimus was 
given at a standard daily oral dose of 0.2 to 0.3 mg/kg per day in 
divided doses every 12 hours starting 12 to 24 hours after the last 
CyA dose had been administered. Dosage adjustments were based 
upon monitoring of trough serum tacrolimus levels by EUSA in 
the early (1989 to early 1994) portion of the study to achieve 
12-hour trough levels of 1.0 to 2.0 ng/mL, and in the latter part of 
the study (mid-1994 to present) by whole-blood MEIA-IMx assay 
to achieve initial12-hour trough levels of 20 to 25 ng/mL within the 
first week. and also according to clinical and biochemical parame-
ters. Additional treatment at the time of tacrolimus conversion in 
the form of bolus high-dose corticosteroids or antilymphocyte 
preparations was not given. Data were analyzed for statistical 
significance by two-tailed Student's t-test or chi-square analysis 
when appropriate. 
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RESULTS 
The criteria for successful graft salvage with tacrolimus 
included a return to or improvement in baseline serum 
creatinine (SCR). and/or improvement on follow-up renal 
biopsy. and/or freedom from dialysis if the patient was 
dialysis-dependent at the time of conversion to tacrolimus. 
With a mean follow-up of 30.0 ::!: 2.4 months (median 36.5 
months. range 12 to 62 months). 159 of 169 patients (94%) 
remain alive and 125 of 169 patients (74%) have achieved 
graft salvage according to the aforementioned criteria. All 
169 patients converted to tacrolimus displayed ongoing 
cellular rejection on preconversion allograft biopsy. Of the 
91 patients with ACR only on preconversion biopsy, 70 
(77%) achieved graft salvage after tacrolimus conversion. 
Of the 62 patients with elements of both ACR plus vascular 
rejection on pre-conversion biopsy, 47 (75%) were salvaged 
(P = NS vs ACR alone). Of the 16 patients with primary 
graft nonfunction and rejection, 8 (50%) were salvaged by 
conversion to tacrolimus (P = .1, ACR vs ACR + vascular 
rejection vs ACR + primary nonfunction). An additional 12 
patients with primary graft function prior to conversion 
became dialysis-dependent as a result of severe ongoing 
rejective during initial CyA therapy. Thus, of 169 patients. 
a total of 28 patients (17%) were dialysis-dependent at the 
time of tacrolimus conversion, and 13 (46%) were success-
fully salvaged and came off dialysis. With a mean follow-up 
of 37.3 ::!: 16.7 months (range 18 to 62 months) following 
conversion, these 13 patients have respective SCR levels of 
1.6, 1.6, 1.7, 1.8, 1.8, 1.9. 2.2, 2.4, 2.5, 2.5, 2.6, 2.6, and 2.8 
mgidL (mean SCR 2.15 :!: 0.37). Excluding the 28 patients 
who were on dialysis at the time of tacrolimus conversion, 
the mean SCR prior to and after conversion in the success-
ful conversions was 3.1 :!: 1.7 mgidL and 2.3 :!: 1.1 mgidL 
(P = .0002 vs preconversion). 
The average preconversion prednisone dose of 28.0 ± 9.0 
mgid has been lowered to 6.6 ± 5.1 mgid, and 28 patients 
(22%) of the 125 with functioning grafts are on tacrolimus 
\llonotherapy. The mean tacrolimus dose has decreased 
from 19.3 ± 9.1 mgid at conversion to 11.3 :!: 6.8 mgid at 
last follow-up (P < .01). Tacrolimus conversion was suc-
cessful in 96 of 133 (72%) CAD and in 29 of 36 (80%) LD 
recipients (P = NS). Successful rescue was also obtained in 
107 of 138 (78%) primary transplants, 13 of 21 (62%) 
second transplants, 3 of 7 (43%) third transplants, 1 of 2 
(50%) fourth transplants, and in the 1 fifth-transplant 
patient (P = .14). Of the 19 recipients of combined 
kidney-pancreas allografts. 18 (95%) were successfully res-
cued. There was no difference in success rates if conversion 
occurred <2 months' (67/86, 78%) or >2 months' (61/83, 
73%) posttransplant or < (921120, 77%) or > (32/49,65%) 
3 months' posttransplant (P = .5 and .13, respectively). 
However, conversion was more successful if performed 
within 6 months of transplantation (77% success) compared 
with> 6 months' posttransplant (50%. P = .006). 
Immunosuppression with either triple·therapy (CyA-ste-
roid-AZA) or double-therapy (CyA-steroids) did not inHu-
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ence the likelihood of it graft salvage after tacrolimus 
conversion (triple therapy: 90 of 117. 77%: double therapy: 
35 of 52, 67%: P = .26). Both patients unsuccessfully 
treated with MMF for rescue prior to referral were success-
fully salvaged with tacrolimus. Of the 144 patients treated 
with antilymphocyte antibody prior to conversion. 117 
(81 %) were salvaged with tacrolimus conversion. 
Since this series was initiated in 19R9. there have been a 
total of 10 deaths. 7 of which occurred in patients who had 
an unsuccessful attempt at graft salvage with tacrolimus 
conversion. Overall. 4 of the \0 deaths (PTLD in 2, sepsis in 
l. and TB in I) were likely related to over immunosuppres-
sion prior to conversion. although an additive effect of 
tacrolimus to the immunosuppressive risk in these patients 
should be considered. Tacrolimus conversion in these 4 
patients (all of whom failed conversion) was in retrospect 
probably ill-advised. None of the remaining 6 deaths could 
be temporally or causally related to tacrolimus conversion. 
Excluding the patients who died, 39 patients referred for 
tacrolimus conversion had prior complications including 
cytomegalovirus (CMV) in 12. renal artery stenosis (RAS) 
in 6, Iymphocele in 5, urine leak in 4, ureteral obstruction in 
4, perforated duodenal ulcer in 1, cardiac arrest in 1, 
cutaneous herpes virus infection in 1, candida esophagitis in 
I, segmental renal infarction with no sequelae in 1, clos-
tridium difficile colitis in 1, aseptic meningitis secondary to 
OKT3 in 1, and myocardial infarction in I. These early 
complications were treated prior to conversion. Thirty of 
these 39 patients (77%) were subsequently rescued. 
There were 35 complications following tacrolimus con-
version including new-onset diabetes mellitus in 9 patients 
(5 requiring insulin therapy, 4 controlled by oral medica-
tion), urinary tract infection in 6, CMV disease in 6, deep 
vein thrombosis in 2, line sepsis in 2, RAS requiring 
angioplasty in 2, bacterial pneumonia in 2, cecal perforation 
in 1, disease recurrence (membranoproliferative glomeru-
lonephritis) in 1, proteinuria in 1, gout in 1, epistaxis in I, 
and a cerebrovascular accident in 1. None of these postcon-
version complications resulted in patient death. 
Causes of Graft Loss After Tacrolimus Conversion 
There were 44 failures (26%) of tacrolimus conversion in 
this group of 169 patients. Eleven patients had repeat 
rejection episodes after initial successful rescue and lost 
their grafts. Twenty-two patients had ongoing renal allo-
graft rejection, which was refractory to tacrolimus conver-
sion. Eight patients with primary allograft non function with 
superimposed rejection were not salvaged, 2 patients lost 
their graft due to noncompliance, and 1 patient died with a 
functioning graft. 
DISCUSSION 
The value of an agent that provides salvage of ongoing 
rejection must be proven in the long term and should 
demonstrate ongoing efficacy in sufficient numbers of pa-
tients. In this large long-term experience with tacrolimus 
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rescue therapy. the majority ( 14411 Ill). R5r:,,) of patients had 
failed prior treatment wit h antilymphocyte preparation~K 
and a subset of 2RIl69 ( 17r;r) of the patients had rejection~ 
severe enough to require ongoing dialysis therapy prior to 
conversion. 
Overall. graft salvage was obtained in 125 of 169 patients 
(74%). an outcome identical to that observed in an initial 
reported series of 77 patientsK~ The mean follow-up of 30 
months reflects the longevity of the salvage effect. In fact. in 
the subgroup of successful rescues from the original series 
of 77 patients. there have been only 9 late graft losses with 
an additional 28 months' follow-up such that 48 of the 57 
patients (84%) originally salvaged continue to have func-
tioning grafts. now with 42 months' follow-up. 10 
In an additional subset of 92 patients who were converted 
to tacrolimus since the original report. the success rate is 
higher than in the earlier study in that 77 patients (840/,:) 
have been successfully rescued. with a mean follow-up of 19 
months (range 12 to 29 months).'1 The reasons for this 
improvement likely reflect a learning curve with the use of 
this drug, earlier conversion before elements of chronic 
rejection are present in the graft, and better patient selec-
tion. We have previously found that grafts with chronic 
rejection without any acute component are unlikely to 
benefit from tacrolimus conversion.!> Patients with ACR 
alone experienced a 77% salvage rate; vascular rejection. 
75%; ACR superimposed on primary allograft nonfunction, 
50% (P = .1). Therefore, histologic severity of rejection 
may not necessarily be a predictor of outcome. 
Lack of reliability of clinical response based on histologic 
criteria prior to conversion has also been observed in two 
recent single-center studies.1I•12 More important may be 
the timing of tacrolimus conversion after transplantation. 
There appears to be a slight but statistically significant 
advantage to conversion < 6 months after transplantation 
in that 114/147 (77%) patients experienced graft salvage 
compared with 11/22 (50%) success if conversion was 
attempted >6 months after transplantation (P = .006). 
Another important feature that appears to be unique to 
tacrolimus as a salvage agent when compared to other 
agents8.9.12 is its ability to provide graft salvage in patients 
who have been on dialysis owing to the severity of rejection. 
Long-term graft salvage was obtained in 13 of 28 such 
patients (46%) resulting in long-term (37.3 :t 16.7 months' 
follow-up) stable allograft function (mean SCR of 2.15 
mg/dL). In those patients not on dialysis preconversion. the 
degree of renal functional impairment did not statistically 
influence the likelihood of successful conversion in that 
those patients with a SCR of < 3 experienced a salvage rate 
of 84% compared with 73% in those patients initially 
presenting with a SCR > 3 (excluding the 28 patients on 
dialysis at the time of conversion) (P = .18). 
One of the most striking observations in our early 
experience with tacrolimus rescue was the ability to taper 
and even stop prednisone therapy in approximately 20% of 
patients successfully salvaged.Y That trend was maintained 
in this expanded experience. and currently 28/125 (22t;C) 
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patients with functioning grafts arc on tacrolimus mono-
therapy. 
Since I l)93. a total of 23 papers have described successful 
salvage of refractory renal allograft rejection with tacroli-
mus. ~with success rates ranging from 527r IJ to 1000 14 in 
both single-center and multicenter North American and 
buropea~ studies. The largest multicenter study to date 
with 73 patients from 14 institutions reported a 78% salvage 
rate.' confirming our original/< and subsequent'! observa-
tions. A total of 382 cases of tacrolimus rescue therapy for 
refractory renal allograft rejection have now been reported 
in the literature. with a mean salvage rate of 75%. 
In addition to the now well-established graft salvage 
effects of tacrolimus. several other agents have shown 
promise as rescue agents. including mycophenolate mofetil 
(MMF)15.16 and perhaps sirolimus.17 MMF has been stud-
ied in a large randomized multicenter trial in which patients 
received either corticosteroids or MMF therapy for refrac-
tory rejection. However. unlike the trials with tacrolimus. 
the MMF study excluded patients on dialysis, pediatric 
patients. third or greater transplants. and patients with 
serum creatinine (SCR) > 5.0 mg/dL. 
In comparing the results of the MMF study to the 
tacrolimus multicenter and Pittsburgh experience by per-
forming a meta-analysis. Woodle has reported similar pa-
tient and graft survival rates in the MMF and tacrolimus 
studies. but significantly less recurrent rejection. incidence 
of CMV, and requirement for antilymphocyte antibody to 
treat recurrent rejection in the tacrolimus studies when 
compared to the MMF study. 1M If the same criteria that 
were used to exclude patients from the MMF study are 
applied to the 169 patients studied at the University of 
Pittsburgh, 70 patients (41 %) would fulfill the entry criteria 
and could be considered a "low-risk" rescue group. The 
remaining 99 patients (59%) would include those on dialy-
sis, greater than third transplant, children, or those with 
initial SCR > 5.0 mg/dL; these could be considered a 
"high-risk" group for rescue. The incidence of CMV in the 
low-risk group was 2% compared with 5% in the high-risk 
group; however. there were 6 retransplants (9%) in the 
low-risk group compared with 25 (25%) in the high-risk 
group. Low-risk patients experienced 6- and I2-month 
patient and graft survival rates (96% and 87%. 96% and 
84%. respectively). which are virtually identical to the 
overall 6-month patient and graft survival reported by the 
MMF arm of the MMF multicenter study (97% and 88%, 
respectively) and are superior to the steroid arm of that 
study (98% and 78%). However, even the "high-risk" 
tacrolimus rescue group had very acceptable outcomes, with 
patient and graft survival of 95% and 76% at 6 months and 
94% and 70,!(- at 12 months. 
Further experience with both MMF and tacrolimus in 
both primary and rescue therapy is necessary to learn how 
best to use these new valuable additions to the pharmaco-
logic armamentarium for transplantation. Clearly. these 
agents need not be mutually exclusive. and can be used in a 
complementary fashion. both for primary therapy19 and 
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perhaps even for rescuc. Optimizing rescue therapy for 
refractory rejection should be individualized for each pa-
tient. Both MMF and tacrolimus are effective in this regard; 
however. tacrolimus appears to have the added advantages 
of providing graft salvage in patients with greatly dimin-
ished renal function (SCR > 5.0). or even in those on 
dialysis. in pediatric patients. those with multiple (>2) 
transplants. while also permitting steroid tapering. It is also 
the only rescue agent thus far to have proven long-term 
efficacy in providing graft salvage. 
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